Abstract
Parkinson’s disease occurs mainly in elderly patients. Among those aged over 80 years, up to 2.6 % are diagnosed with Parkinson’s disease (de Rijk et al. 2000). At onset of the disease, approximately 70 % of individuals were 50 years or older. As for dementia, a significant increase in its incidence is expected, with the consequence that in 2030 twice the number of patients will have to be treated for Parkinson’s disease if compared with current rates. Besides these data concerning primary Parkinson’s disease, there will also be an even more increasing prevalence of nonprimary parkinsonian syndromes. To date, nonprimary parkinsonian syndromes or partial symptoms thereof are reaching prevalence rates up to 51 % in some subgroups of the elderly population (Bennett et al. 1996). Among nonprimary forms, drug-induced syndromes are most common, and other causes such as postinfectious, metabolic, and toxic ones are rare. The prevalence of drug-induced parkinsonian syndromes remains less clear, but reports found it to be up to 50 % in nursing home residents (Stephen and Williamson 1984). As this figure seems alarmingly high, ruling out drug-induced parkinsonian syndromes is very important as otherwise correct treatment opportunities will be missed, causing serious disadvantages for the patient. Needless to say, in drug-induced parkinsonian syndromes, the responsible drug has to be identified and discontinued instead of adding levodopa treatment.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Aarsland D, Zaccai J, Brayne C (2005) A systematic review of prevalence studies of dementia in Parkinson’s disease. Mov Disord 20:1255–1263
Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71–76
Brooks DJ (2004) Safety and tolerability of COMT inhibitors. Neurology 62(Suppl 1):S39–S46
Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH (2005) Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 28:215–219
Csoti I, Fornadi F (2008) Medikamentöse Interaktionen in der Parkinson-Therapie. NeuroGeriatrie 5:160–168
de Rijk MC, Launer LJ, Berger K (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(11 Suppl 5):S21–S23
Dell’Ágnello G, Ceravolo R, Nuti A et al (2001) SSRIs do not worsen Parkinson’s disease: evidence from an open-label, prospective study. Clin Neuropharmacol 24:221–227
Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351:2509–2518
Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508
German Society for Neurology (2009) Leitlinien der Deutschen Gesellschaft für Neurologie 2008. Parkinson-syndrome. Diagnostik und Therapie. http://www.dgn.org. Accessed 18 Dec 2009
Goetz CG, Blasucci LM, Leurgans S, Pappert EJ (2000) Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55:789–794
Holroyd S, Currie L, Wooten GF (2001) Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry 70:734–738
Janno S, Holi M, Tuisku K, Wahlbeck K (2004) Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia in patients. Am J Psychiatry 161:160–163
Jenner P (2005) A novel dopamine agonist for the transdermal treatment of Parkinson’s disease. Neurology 65(2 Suppl 1):S3–S5
Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev CD004747
Mitchell SL, Sullivan EA, Lipsitz LA (1997) Exclusion of elderly subjects from clinical trials for Parkinson disease. Arch Neurol 54:1393–1398
National Collaborating Centre for Chronic Conditions (UK) (2006) Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. Royal College of Physicians (UK), London. National Institute for Health and Clinical Excellence: guidance. http://www.ncbi.nlm.nih.gov/pubmed/21089238. Accessed 17 Aug 2011
Nutt JG (2003) Long-term levodopa therapy: challenges to our understanding and for the care of people with Parkinson’s disease. Exp Neurol 184:9–13
Parkinson Study Group (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183
Parkinson Study Group (2000) A randomized controlled trial comparing pramipexole with levodopa in early Parkinson’s disease: design and methods of the CALM-PD Study. Clin Neuropharmacol 23:34–44
Poewe WH, Wenning GK (1998) The natural history of Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S1–S9
Pollak P, Tison F, Rascol O et al (2004) Clozapine in drug induced psychosis in Parkinson’s disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 75:689–695
Quinn N, Critchley P, Marsden CD (1987) Young onset Parkinson’s disease. Mov Disord 2:73–91
Rascol O, Brooks DJ, Melamed E et al (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once Daily, study): a randomised, double-blind, parallel-group trial. Lancet 365(9463):947–954
Reddy S, Factor SA, Molho ES, Feustel PJ (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17:676–681
Santamaría J, Tolosa E, Valles A (1986) Parkinson’s disease with depression: a possible subgroup of idiopathic parkinsonism. Neurology 36:1130–1133
Silver D (2006) Impact of functional age on the use of dopamine agonists in patients with Parkinson disease. Neurologist 12:214–223
Splinter MY (2007) Rotigotine: transdermal dopamine agonist treatment of Parkinson’s disease and restless legs syndrome. Ann Pharmacother 41:285–295
Starkstein SE, Preziosi TJ, Bolduc PL, Robinson RG (1990) Depression in Parkinson’s disease. J Nerv Ment Dis 178:27–31
Stephen PJ, Williamson J (1984) Drug-induced parkinsonism in the elderly. Lancet 2(8411):1082–1083
U.S. Department of Health and Human Services. American Medical Directors Association (AMDA). Parkinson's disease. Columbia (MD). 2010 http://www.guideline.gov/content.aspx?id=9628&search=parkinson. Accessed Dec 2011
Wood LD, Neumiller JJ, Setter SM, Dobbins EK (2010) Clinical review of treatment options for select nonmotor symptoms of Parkinson’s disease. Am J Geriatr Pharmacother 8:294–315
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer-Verlag Wien
About this chapter
Cite this chapter
Burkhardt, H. (2013). Parkinson’s Disease. In: Wehling, M. (eds) Drug Therapy for the Elderly. Springer, Vienna. https://doi.org/10.1007/978-3-7091-0912-0_13
Download citation
DOI: https://doi.org/10.1007/978-3-7091-0912-0_13
Published:
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-0911-3
Online ISBN: 978-3-7091-0912-0
eBook Packages: MedicineMedicine (R0)